Design evaluation and optimization for models of hepatitis C viral dynamics

Statistics in Medicine

Volumn 30, Issue 10, 2011, Pages 1045-1056

  Guedj, Jeremie ^a,b   Bazzoli, Caroline ^c   Neumann, Avidan U ^b,d   Mentré, France ^c  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b BAR ILAN UNIVERSITY   (Israel)

^c INSERM   (France)

^d SANTA FE INSTITUTE   (United States)

Author keywords

Design evaluation; Design optimization; Hepatitis C; Non linear mixed effect models; Ordinary differential equations; Viral kinetics

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ARTICLE; DATA ANALYSIS SOFTWARE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LEARNING ALGORITHM; LINEAR SYSTEM; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; NONHUMAN; NONLINEAR SYSTEM; NORMAL DISTRIBUTION; OUTCOME ASSESSMENT; PROCESS OPTIMIZATION; SYSTEMATIC ERROR; TREATMENT PLANNING; TREATMENT RESPONSE; VALIDATION PROCESS; VIRUS LOAD; VIRUS MORPHOGENESIS; VIRUS PATHOGENESIS;

COMPUTER SIMULATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MODELS, BIOLOGICAL; MODELS, STATISTICAL; POLYETHYLENE GLYCOLS; RESEARCH DESIGN;

EID: 79954595958     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4191     Document Type: Article

References (38)

1. Shepard C, Finelli L, Alter M. Global epidemiology of hepatitis C virus infection. Lancet Infectious Diseases 2005; 5(9):558-567.
2. Awad KT, Thorlund HG, Hauser G, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis c: a systematic review of randomized trials. Hepatology 2010; 51(4):1176-1184.
3. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-107.
4. Mihm U, Herrmann E, Sarrazin C, Zeuzem S. Review article: predicting response in hepatitis C virus therapy. Alimentary Pharmacology and Therapeutics 2006; 23(8):1043-1054.
5. Talal A, Ribeiro R, Powers K, Grace M, Cullen C, Hussain M, Markatou M, Perelson A. Pharmacodynamics of PEG-IFN differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology 2006; 43:943-953.
6. Miao H, Xia X, Perelson A, Wu H. On identifiability of nonlinear ODE models with applications in viral dynamics. SIAM Review 2011; 53(1).
7. Saccomani M. An effective automatic procedure for testing parameter identifiability of HIV/AIDS models. Bulletin of Mathematical Biology 2010. DOI: 10.1007/s11538-010-9588-2.
8. Xia X, Moog CH. Identifiability of nonlinear systems with applications to HIV/AIDS models. IEEE Transactions on Automatic Control 2003; 48:330-336.
9. Wu H, Zhu H, Miao H, Perelson A. Parameter identifiability and estimation of HIV/AIDS dynamic models. Bulletin of Mathematical Biology 2008; 70(3):785-799.
10. Han C, Chaloner K. Design of population studies of HIV dynamics. In Deterministic and Stochastic Models of AIDS Epidemics and HIV Infections with Intervention, Tan W, Wu H (eds). World Scientific Pub. Co Inc.: Singapore, 2005.
11. Guedj J, Thiebaut R, Commenges D. Practical identifiability of HIV dynamics models. Bulletin of Mathematical Biology 2007; 69(8):2493-2513.
12. Miao H, Dykes C, Demeter L, Cavenaugh J, Park S, Perelson A, Wu H. Modeling and estimation of kinetics parameters and replicative fitness of HIV-1 from flow-cytometry-based growth competition experiments. Bulletin of Mathematical Biology 2008; 70(6):1749-1771.
13. Lavielle M, Samson A, Fermin A, Mentré Maximum likelihood estimation of long-term HIV dynamic models and antiviral response. Biometrics, DOI: 10.1111/j.1541-0420.2010.01422.x.
14. Mentré F, Mallet A, Baccar D. Optimal design in random-effects regression models. Biometrika 1997; 84:429-442.
15. Bazzoli C, Retout S, Mentré F. Fisher information matrix for nonlinear mixed effects multiple response models: evaluation and comparison by simulation to results from FO, FOCE and SAEM algorithms. Statistics in Medicine 2009; 28(14):1940-1956.
16. Bazzoli C, Retout S, Mentré F. Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0. Computer Methods and Programs in Biomedicine 2010; 98:55-65.
17. Dixit N, Layden-Almer J, Layden T. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2005; 432:922-924.
18. Herrmann E, Neumann A, Schmidt J, Zeuzem S. Hepatitis C virus kinetics. Antiviral Therapy 2000; 5(2):85-90.
19. Guedj J, Rong L, Dahari H, Perelson A. A perspective on modeling hepatitis C virus infection. Journal of Viral Hepatitis 2010; 17(12):825-833.
20. Atkinson A, Donev A. Optimum Experimental Designs. Oxford University Press: Oxford, 1992.
21. Retout S, Comets E, Samson A, Mentré F. Design in nonlinear mixed effects models: optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates. Statistics in Medicine 2007; 26(28):5162-5179.
22. Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, Gianfranco E, Vrolijk JM, Esteban JI, Hezode C, Lagging M, Negro F, Soulier A, Verheij-Hart E, Hansen B, Tal R, Ferrari C, Schalm SW, Neumann AU. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. Journal of Hepatology 2005; 43(2):250-257.
23. Sherman K, Shire N, Rouster S, Peters M, James KM, Chung R, Horn P. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology 2005; 128(2):313-327.
24. Herrmann E. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37(6):1351-1358.
25. Zeuzem S, Herrmann E, Lee J, Fricke J, Neumann A, Modi M, Colucci G, Roth W. Viral kinetics in patients with chronic hepatitis c treated with standard or peginterferon α2a. Gastroenterology 2001; 120(6):1438-1447.
26. Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiochhi L, Filice G. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antiviral Therapy 2004; 9:491-498.
27. Dahari D, AffonsodeAraujo E, Haagmans B, Layden J, Cotler S, Barone A, Neumann AU. Pharmacodynamics of PEG-IFN alpha-2a in hiv/hcv co-infected patients: Implications for treatment outcomes. Journal of Hepatology 2010 53(3):460-467.
28. Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Computational Statistic and Data Analysis 2005; 49:1020-1038.
29. Bates D, Watts D. Relative curvature measures of nonlinearity. Journal of the Royal Statistical Society. Series B (Methodological) 1980; 42:1-25.
30. Tan W, Wu H. Deterministic and Stochastic Models of AIDS Epidemics and HIV Infections with Intervention. World Scientific: Singapore, 2005.
31. Jones B, Wang J. Constructing optimal designs for fitting pharmacokinetic models. Statistics and Computing 1999; 9(3):209-218.
32. Retout S, Mentré F, Bruno R. Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics. Statistics in Medicine 2002; 21(18):2623-2639.
33. Neumann A, Layden T, Reddy K, Levi-Drummer R, Poulakos 2nd J. The 2nd phase slope of HCV decline is highly predictive of sustained virologic response following consensus IFN treatment for chronic hepatitis C and is determined by genotype but not dose. Hepatology 2000; 32:356A.
34. Han C, Chaloner K, Perelson A. Bayesian analysis of a population HIV dynamic model. Case Studies in Bayesian Statistics 2002; 6:223-237.
35. Han C, Chaloner K. Bayesian experimental design for nonlinear mixed-effects models with application to HIV dynamic. Biometrics 2004; 60:25-33.
36. Thiébaut R, Guedj J, Jacqmin-Gadda H, Chêne G, Trimoulet P, Neau D, Commenges D. Estimation of dynamical model parameters taking into account undetectable marker values. BMC Medical Research Methodology 2006; 6(1):1-10.
37. Guedj J, Neumann A. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. Journal of Theoretical Biology 267(3):330-340.
38. Retout S, Comets E, Thus C, Mentré F. Design optimization in nonlinear mixed effects models using cost functions: application to a joint model of infliximab and methotrexate pharmacokinetics. Communications in Statistics-Theory and Methods 2009; 38(18):3351-3368.